Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 14/20 | 0.64 |
| ▸ | CPT1B | Q92523 | 14/20 | 0.64 |
| ▸ | CPT2 | P23786 | 11/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571441 | 0.95 | CPT1A (0.68) | CPT1ACPT1BCPT2MAPT | |
| SCHEMBL3579890 | 0.90 | CPT1A (0.78) | CPT1ACPT1BCPT2MAPTLMNA | |
| SCHEMBL3572627 | 0.89 | CPT1A (0.79) | CPT1ACPT1BCPT2MAPTLMNA | |
| SCHEMBL3582869 | 0.88 | CPT1A (0.78) | CPT1ACPT1BCPT2MAPT | |
| SCHEMBL30015638 | 0.88 | CPT1A (0.80) | CPT1ACPT1BCPT2MAPT | |
| SCHEMBL3569896 | 0.88 | CPT1A (0.80) | CPT1ACPT1BCPT2MAPT | |
| SCHEMBL3573402 | 0.88 | CPT1A (0.65) | CPT1ACPT1BCPT2MAPT | |
| SCHEMBL752101 | 0.87 | CPT1A (0.79) | CPT1ACPT1BCPT2MAPTLMNA | |
| SCHEMBL3580790 | 0.87 | CPT1A (0.60) | CPT1ACPT1BCPT2MAPT | |
| SCHEMBL3572838 | 0.86 | CPT1A (0.82) | CPT1ACPT1BCPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT1B 2/4885CPT2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.